Abstract

Songuigama Coulibaly¹, Jean-Paul D.U. N'Guessan¹, Jean-Fabrice K. Koffi ^1,2, Soro T. Grâce¹ and Mahama Ouattara^1*

The treatment of tuberculosis (TB) faces several challenges, such as the emergence of drug-resistant TB, long treatment duration, management of latent TB, and toxic adverse effects leading to non-compliance with treatment. To address this, WHO encourages the search for new molecules that are more effective and better tolerated. In this context, hybrid molecules of the 5-nitro heteroaryl-phenylpropenone type have been designed as new anti-tuberculosis drugs. These compounds were developed by molecular hybridization, combining a pentagonal 5-nitro heteroaryl with a phenylpropenone functional chain. Four derivatives were synthesized by condensation of a 5-nitro heteroaryl carbaldehyde derivative and a selected ketone, with yields ranging from 20 to 74%. Their structure was confirmed by spectroscopic methods. These new compounds must now be evaluated on different strains of Mycobacterium tuberculosis to confirm their anti-tuberculosis potential.

Anti-tuberculous; Chalcones; Heteroaryl pentagonals; 5-nitro heteroaryl-phenylpropenone

[ View HTML Full Text]